CTLA4 and melanoma: The emergence of some novel therapies against melanoma such as genetically targeted therapies (e.g., BRAF inhibitors) and immunotherapies (e.g., PD-1/PD-L1 and CTLA-4 antibodies) has undoubtedly improved melanoma treatment, but the overall prognosis of patients remains poor [2, 3].